Competitive intelligence study of a non-viral vector for gene therapy of Parkinson´s disease (Cinvestav-PX-001)

Introduction Cinvestav-PX-001 is a nanoparticle-based gene delivery system capable of targeting therapeutic genes to dopaminergic neurons in the brain and therefore induces a site-directed therapy for Parkinson's disease (PD).... [ view full abstract ]

Introduction
Cinvestav-PX-001 is a nanoparticle-based gene delivery system capable of targeting therapeutic genes to dopaminergic neurons in the brain and therefore induces a site-directed therapy for Parkinson's disease (PD). Experiments in rats with PD-like lesions suggest that this treatment helps to restore dopaminergic function and improve motor symptoms. Cinvestav-PX-001 may have significant commercial potential. This new treatment is safer compared to more commonly used viral vectors for therapeutic indication of PD, because they can induce adverse side effects. Competitive advantages include: high neuronal specificity in addressing the long-term transgene expression, safety and a simple, reproducible and cost-effective synthesis. The aim of this study was to obtain the competitive outlook of the available technologies related with the use of a non-viral vector for gene therapy of PD and thus provide support for strategic decisions in our organization based on the position of intellectual property.
Methods
A prior art analysis based on patents and scientific documents was performed to identify potential competing patents. We applied analysis tools for designing commercialization strategy and these include: a) technological and competitive intelligence, b) market research (size, segments, trends, drivers and growth potential) and c) regulatory environment, in which the technology competes. These aspects were analyzed in order to improve the timeliness and quality of inputs to the decision process.
Results and Discussion
The invention is directed to the market of supplies for gene therapy, the projected growth for the market is up to 2.8 trillion on 2024, and the main leading companies are located in United States, Japan, United Kingdom, France, Germany, Italy and Spain. As a result of this analysis, the commercialization strategy for Cinvestav-PX-001 considers provide a non-exclusive license to an international licensee in USA and/or Europe with the experience and ability to complete its commercial development (clinical phase and regulatory affairs) and the creation of a spinoff company from Cinvestav with innovative vision in new therapeutic applications of Cinvestav-PX-001.
Project supported by Fund of Innovation (Finnova 224222), Ministry of Economy and Conacyt Mexico. We appreciate the support of ISIS Enterprise and Newton Fund in IP analysis.